Aurealis Entered into an Exclusive License and Collaboration Agreement with Xbiome for AUP-16 to Treat Diabetic Foot Ulcer and Inflammatory Disease
Shots:
- Aurealis to receive up front, development milestones & is eligible to receive commercial milestones with a total consideration of $139M along with royalties on product sales and will be responsible for the global development of the product
- Xbiome obtains exclusive rights for Aurealis’s AUP-16 in Mainland China, Hong Kong, Macao, and Taiwan & will lead the clinical and other development, regulatory submissions & commercialization of the licensed products in the licensed country
- Additionally, Aurealis obtains the rights to AUP-16 outside of the specified territory. AUP-16 is a genetically engineered Lactococcus lactis expressing FGF2, bFGF, IL4, and mCSF
Ref: PR Newswire | Image: CB Insights
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
